OPRX
OptimizeRx Corp.
$6.51
-0.18
(-2.69%)
Mkt Cap
122.16M
Volume
222,439
52W Range
4.54-22.25
Sector
Healthcare
Beta
1.08
EPS (TTM)
0.37
P/E Ratio
17.77
Revenue (TTM)
107.34M
Rev Growth (5Y)
+20.4%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$53.95
Undervalued
strong signal
87.9% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109.43M | 92.13M | 71.52M | 62.45M | 61.29M | 43.31M | 24.60M | 21.21M | 12.13M | 7.75M | 7.22M | 6.50M |
| Net Income | 5.13M | (20.11M) | (17.57M) | (11.44M) | 378,079 | (2.21M) | (3.14M) | 226,344 | (2.10M) | (1.54M) | (595,140) | (1.03M) |
| EPS | 0.28 | -1.10 | -1.03 | -0.64 | 0.02 | -0.15 | -0.23 | 0.02 | -0.21 | -0.16 | -0.07 | -0.14 |
| Free Cash Flow | 18.66M | 4.78M | (8.11M) | 10.41M | 240,040 | (6.44M) | (3.25M) | 701,542 | (1.52M) | (815,503) | 414,146 | (466,302) |
| FCF / Share | 1.01 | 0.26 | -0.47 | 0.59 | 0.01 | -0.43 | -0.24 | 0.06 | -0.16 | -0.08 | 0.05 | -0.06 |
| Operating CF | 18.71M | 4.89M | (7.24M) | 10.65M | 726,039 | (6.31M) | (1.66M) | 792,555 | (1.48M) | (465,965) | 515,110 | (56,350) |
| Total Assets | 176.92M | 171.17M | 183.37M | 134.65M | 140.99M | 60.33M | 56.64M | 25.05M | 9.76M | 11.48M | 12.31M | 7.03M |
| Total Debt | 26.10M | 33.19M | 36.82M | 234,434 | 327,708 | 448,753 | 564,184 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 23.36M | 13.38M | 13.85M | 18.21M | 84.68M | 10.52M | 18.85M | 8.91M | 5.12M | 7.03M | 8.21M | 3.45M |
| Book Value | 128.29M | 117.00M | 126.55M | 126.11M | 131.38M | 49.97M | 44.86M | 18.46M | 6.22M | 7.81M | 8.94M | 4.61M |
| Return on Equity | 0.04 | -0.17 | -0.14 | -0.09 | 0.00 | -0.04 | -0.07 | 0.01 | -0.34 | -0.20 | -0.07 | -0.22 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.84M | 32.24M | 26.07M | 29.20M | 21.93M | 32.32M | 21.31M | 18.81M | 19.69M | 28.37M | 16.33M | 13.82M |
| Net Income | (495,000) | 5.02M | 779,000 | 1.53M | (2.20M) | (78,000) | (9.12M) | (4.01M) | (6.90M) | (4.14M) | (2.87M) | (4.16M) |
| EPS | -0.03 | 0.27 | 0.04 | 0.08 | -0.12 | -0.00 | -0.50 | -0.22 | -0.38 | -0.23 | -0.17 | -0.24 |
| Free Cash Flow | (488,000) | 7.08M | 3.19M | 4.55M | 3.84M | 78,000 | 1.70M | 697,000 | 1.97M | (6.26M) | 1.15M | (2.39M) |
| FCF / Share | -0.03 | 0.38 | 0.17 | 0.25 | 0.21 | 0.00 | 0.09 | 0.04 | 0.11 | -0.35 | 0.07 | -0.14 |
| Operating CF | (467,000) | 7.09M | 3.20M | 4.56M | 3.86M | 198,000 | 1.79M | 782,000 | 2.12M | (6.26M) | 1.47M | (2.37M) |
| Total Assets | 167.26M | 176.92M | 170.32M | 169.26M | 167.77M | 171.17M | 165.20M | 172.88M | 176.37M | 183.37M | 123.93M | 121.32M |
| Total Debt | 23.72M | 26.10M | 28.61M | 28.98M | 32.80M | 33.19M | 35.72M | 36.09M | 36.46M | 36.82M | 148,642 | 14,545 |
| Cash & Equiv | 20.17M | 23.36M | 19.52M | 16.59M | 16.57M | 13.38M | 16.13M | 14.96M | 15.18M | 13.85M | 9.92M | 9.81M |
| Book Value | 129.61M | 128.29M | 122.26M | 119.28M | 116.27M | 117.00M | 114.47M | 121.02M | 122.54M | 126.55M | 116.11M | 115.82M |
| Return on Equity | -0.00 | 0.04 | 0.01 | 0.01 | -0.02 | -0.00 | -0.08 | -0.03 | -0.06 | -0.03 | -0.02 | -0.04 |
OPRX News
OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent
OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms
OptimizeRx to Participate in Upcoming Investor Conferences
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx's Authenticated EHR Network
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?
OptimizeRx Q1 Earnings Call Highlights
OptimizeRx Corporation (OPRX) Q1 2026 Earnings Call Transcript